Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Lab supplier Merck KGaA says U.S. Defense Production Act poses challenge

Stock MarketsMay 12, 2021 05:56AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016. REUTERS/Ralph Orlowski/File Photo

By Ludwig Burger

FRANKFURT (Reuters) - Merck KGaA on Wednesday said that U.S. regulations that give priority to U.S. government contracts to purchase COVID-19 vaccines are a challenge as it seeks to meet soaring demand for its lab equipment and supplies across the globe.

"We are actively expanding our capacity to be able to supply this unprecedented and ever increasing demand. Is this being a challenge? Obviously it is being a challenge," Chief Executive Belen Garijo said in a media briefing when asked what impact the U.S. Defense Production Act is having on its ability to serve vaccine makers elsewhere in the world.

She said U.S. law required that a preference be given to so-called rated state orders for COVID-19 programmes over any other orders.

"For us, all our customers and all the other COVID-19 programmes are very crucial and we are making capacity expansion a top priority of our agenda," she said, pointing to investment projects both in the United States and Europe.

Under the U.S. priority access programme, the government has laid claim not only to finished COVID-19 vaccines but also to vaccine components and equipment.

Germany's CureVac, which is gearing up to publish results of a COVID-19 vaccine trial, said last week that U.S. export restrictions on already tight supplies of materials were making it impossible to predict its short-term production ramp-up in Europe.

Merck in March unveiled plans to invest 25 million euros ($29.9 million) to make disposable plastic materials for bioreactors in France, an essential input for COVID-19 vaccine manufacturing.

The new site, Merck's first such facility in Europe, will likely come on stream at the end of this year, Garijo reiterated on Wednesday.

Merck in December announced a combined $47 million investment at U.S. production facilities in Massachusetts and New Hampshire, also to produce supplies for makers of COVID-19 vaccines and therapies.

Merck, which competes in lab equipment with Thermo Fisher (NYSE:TMO) and Sartorius, has another site for single-use plastic bags for bioreactors in Wuxi, China.

Lab supplier Merck KGaA says U.S. Defense Production Act poses challenge
 

Related Articles

Take Advantage of These 3 Top Momentum Stocks
Take Advantage of These 3 Top Momentum Stocks By StockNews - Jun 14, 2021

Benchmark indices have been soaring lately, hitting fresh highs as the U.S. economy continues to recover at an impressive pace. And because analysts expect the Fed to maintain its...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email